8-K: Exelixis Q3 2025 Earnings Soar, Boosts Guidance & Buyback

Exelixis reported strong third-quarter 2025 financial results with significant revenue and EPS growth, raised its full-year financial guidance, and authorized a new $750 million stock repurchase program.

Summary

• Total revenues for Q3 2025 increased to $597.8 million, up from $539.5 million in Q3 2024.
• Net product revenues for the cabozantinib franchise in the U.S. were $542.9 million in Q3 2025, an increase from $478.1 million in Q3 2024, primarily due to increased sales volume.
• GAAP diluted EPS for Q3 2025 was $0.69, compared to $0.40 in Q3 2024, favorably impacted by lower weighted-average common shares outstanding.
• Non-GAAP diluted EPS for Q3 2025 was $0.78, up from $0.47 in Q3 2024.
• Research and development expenses decreased to $199.2 million in Q3 2025 from $222.6 million in Q3 2024, mainly due to lower clinical trial and collaboration costs.
• The company incurred $19.8 million in restructuring expenses in Q3 2025 related to a corporate reorganization plan, including workforce adjustments and closing an office in King of Prussia, Pennsylvania, with total estimated charges of $20.5 million.
• Exelixis updated its fiscal year 2025 guidance, increasing the lower end of total revenue and net product revenue ranges, significantly lowering R&D expense guidance to $850 million $900 million, and reducing the effective tax rate guidance to 17% 18%.
• Detailed positive results from the STELLAR-303 pivotal trial for zanzalintinib in combination with atezolizumab in advanced colorectal cancer were presented at ESMO 2025 and published in The Lancet, meeting one dual primary endpoint with a statistically significant reduction in the risk of death.
• Exelixis intends to submit a New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for previously treated metastatic CRC in the U.S. before year-end 2025.
• The Board of Directors authorized a new stock repurchase program of up to $750 million of common stock before December 31, 2026, marking the fifth such program since March 2023.
• Since March 2023, Exelixis has returned $1.9 billion to shareholders through stock repurchase programs, reducing weighted-average diluted common shares outstanding from 326.3 million to 278.5 million as of September 30, 2025.
• The One Big Beautiful Bill Act, signed in July 2025, provides an estimated federal cash tax benefit of $147 million for previously unamortized domestic R&E expenditures.

Sentiment

Score: 8

Explanation: The filing indicates strong financial performance with significant revenue and EPS growth, coupled with increased full-year guidance and a substantial new stock repurchase program. Positive clinical trial results for a key pipeline asset (zanzalintinib) and expanded regulatory approvals for CABOMETYX further bolster the company's strategic position and future prospects. While restructuring expenses represent a short-term negative, the overall outlook is highly positive.

Positives

• Total revenues increased to $597.8 million in Q3 2025 from $539.5 million in Q3 2024, demonstrating strong top-line growth.
• Net product revenues for the cabozantinib franchise grew to $542.9 million in Q3 2025, driven by increased sales volume.
• GAAP diluted EPS significantly increased to $0.69 in Q3 2025 from $0.40 in Q3 2024, partly due to effective stock repurchase programs.
• Non-GAAP diluted EPS also saw substantial growth, reaching $0.78 in Q3 2025 compared to $0.47 in Q3 2024.
• Research and development expenses decreased to $199.2 million in Q3 2025 from $222.6 million in Q3 2024, indicating improved cost management or shifting development phases.
• Full-year 2025 total revenue guidance was raised, with the new range of $2.30 billion $2.35 billion, reflecting increased confidence in future sales.
• Full-year 2025 R&D expense guidance was significantly lowered to $850 million $900 million, suggesting greater efficiency in development spending.
• The effective tax rate guidance for FY2025 was reduced to 17% 18%, which will positively impact net income.
• Positive detailed results from the STELLAR-303 pivotal trial for zanzalintinib in advanced colorectal cancer, demonstrating a statistically significant reduction in the risk of death, support pipeline strength.
• Regulatory approvals for CABOMETYX in advanced neuroendocrine tumors by the European Commission, Brazil, and Australia expand market access.
• A new stock repurchase program of up to $750 million was authorized, signaling management's commitment to enhancing shareholder value.
• The company expects a federal cash tax benefit of $147 million from the One Big Beautiful Bill Act, improving cash flow.

Negatives

• Collaboration revenues decreased to $54.8 million in Q3 2025 from $61.5 million in Q3 2024, primarily due to lower milestone-related revenues and development cost reimbursements.
• Selling, general and administrative expenses increased to $123.7 million in Q3 2025 from $111.8 million in Q3 2024, mainly due to higher stock-based compensation and consulting costs.
• Restructuring expenses of $19.8 million were incurred in Q3 2025 as part of a corporate reorganization plan, which includes workforce adjustments and an office closure.

Risks

• The degree of market acceptance of CABOMETYX and other Exelixis products in approved indications and territories, and the ability to obtain or maintain coverage and reimbursement for these products.
• The effectiveness of CABOMETYX and other Exelixis products in comparison to competing products.
• The level of costs associated with commercialization, research and development, in-licensing or acquisition of product candidates, and other activities.
• The ability to maintain and scale adequate sales, marketing, market access, and product distribution capabilities or to enter into and maintain agreements with third parties to do so.
• The potential failure of cabozantinib, zanzalintinib, and other product candidates, alone and in combination with other therapies, to demonstrate safety and/or efficacy in clinical testing.
• Uncertainties inherent in the drug discovery and product development process.
• Dependence on relationships with collaboration partners, including their pursuit of regulatory approvals, adherence to agreements, and investment in resources.
• Complexities and unpredictability of regulatory review and approval processes in the U.S. and elsewhere.
• Continuing compliance with applicable legal and regulatory requirements.
• Unexpected concerns that may arise from adverse safety events or additional data analyses of clinical trials.
• Dependence on third-party vendors for the development, manufacture, and supply of products and product candidates.
• The ability to protect intellectual property rights.
• Market competition, including the potential for competitors to obtain approval for generic versions of marketed products.
• Changes in economic and business conditions, including as a result of changing trade policies and tariffs and related uncertainty.
• Plans to submit a New Drug Application for zanzalintinib are subject to limitations on the availability of government services, such as from the FDA, as a result of the ongoing U.S. federal government shutdown.

Future Outlook

Exelixis plans to submit its first New Drug Application for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer in the U.S. before year-end 2025. The company is also planning additional zanzalintinib pivotal trials in post-chemotherapy adjuvant CRC settings and high-grade/recurrent meningiomas, and aims to advance promising early-stage pipeline candidates into full development. The corporate reorganization plan is expected to be substantially completed by the end of fiscal year 2025. Exelixis has updated its fiscal year 2025 financial guidance, raising revenue expectations while lowering R&D expense and effective tax rate guidance. A new stock repurchase program of up to $750 million is authorized through December 31, 2026.

Management Comments

• Michael M. Morrissey, Ph.D., President and Chief Executive Officer, stated: "Exelixis gained momentum in the cabozantinib franchise and delivered on critical strategic priorities across the research & development portfolio."
• Morrissey also noted: "The cabozantinib franchise continued to outperform with sustained growth in renal cell carcinoma and neuroendocrine tumors, where CABOMETYX built on its position as the leading oral therapy for new patient market share in second-line and later settings."
• Regarding zanzalintinib, Morrissey commented: "Based on these results, we intend to complete the submission of our first new drug application for zanzalintinib in the U.S. before year-end."
• Morrissey further highlighted: "We also made strong progress across the range of ongoing and planned zanzalintinib pivotal trials, as well as the four ongoing phase 1 clinical studies from our early-stage pipeline where were looking to profile and move the most promising candidates into full development."

Industry Context

Exelixis operates in the highly competitive and innovation-driven oncology pharmaceutical industry. The continued strong performance of its flagship product, CABOMETYX, in established indications like renal cell carcinoma and its expansion into neuroendocrine tumors, both in the U.S. and internationally, demonstrates its ability to capture and grow market share against existing therapies. The positive clinical trial results for zanzalintinib in advanced colorectal cancer, a challenging indication, position it as a potential new entrant in a market with significant unmet needs. The company's focus on advancing a diverse pipeline of small molecules and biotherapeutics, including antibody-drug conjugates, aligns with broader industry trends towards targeted therapies and combination regimens to improve patient outcomes. The strategic stock repurchases reflect a mature company with strong cash flow, a common practice among established pharmaceutical firms to return value to shareholders.

Comparison to Industry Standards

• CABOMETYX (cabozantinib) has established itself as the leading oral therapy for new patient market share in second-line and later settings for neuroendocrine tumors, indicating strong competitive performance against other approved oral therapies in this space.
• The STELLAR-303 pivotal trial for zanzalintinib in combination with atezolizumab (Tecentriq, Genentech/Roche) demonstrated a statistically significant reduction in the risk of death versus regorafenib (Stivarga, Bayer) in previously treated non-MSI-high metastatic colorectal cancer. This outcome is a significant achievement in a difficult-to-treat patient population, positioning zanzalintinib favorably against an established standard of care.
• The initiation of the STELLAR-311 phase 3 pivotal trial evaluating zanzalintinib versus everolimus (Afinitor, Novartis) as a first oral therapy in advanced NET indicates Exelixis is directly challenging another established therapy in the NET treatment landscape.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased guidance, and a new $750 million stock repurchase program, which is expected to reduce share count and enhance shareholder value.
• Employees: Negative impact for employees affected by the corporate reorganization plan, which includes workforce adjustments and the closure of an office, leading to severance and potential job losses.
• Patients: Positive impact from the continued development and regulatory approvals of cancer treatments like CABOMETYX and zanzalintinib, offering new or improved therapeutic options for various cancer types.

Next Steps

• Complete the submission of a New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for the treatment of patients with previously treated metastatic colorectal cancer in the U.S. before year-end 2025.
• Proceed to the planned final analysis for the overall survival (OS) endpoint in patients without liver metastases for the STELLAR-303 trial.
• Initiate additional zanzalintinib pivotal trials, including in post-chemotherapy adjuvant colorectal cancer settings, as well as in high grade and/or recurrent meningiomas.
• Profile and move the most promising candidates from the four ongoing phase 1 clinical studies (XL309, XB010, XB628, XB371) into full development.
• Substantially complete the corporate reorganization plan by the end of fiscal year 2025.
• Complete repurchases under the February 2025 stock repurchase program in the fourth quarter of 2025.
• Execute the newly authorized $750 million stock repurchase program before December 31, 2026.

Key Dates

Recommendation

Exelixis delivered robust financial results for Q3 2025, significantly outperforming the prior year in both revenue and EPS. The company raised its full-year revenue guidance while simultaneously lowering its R&D expense and effective tax rate guidance, indicating improved operational efficiency and a stronger profitability outlook. Key pipeline asset zanzalintinib showed positive pivotal trial results (STELLAR-303) with an impending NDA submission, and CABOMETYX secured new global approvals, demonstrating strong product lifecycle management and market expansion. The authorization of a new $750 million stock repurchase program underscores management's confidence and commitment to shareholder returns. These factors collectively present a highly compelling investment thesis, suggesting significant upside potential.

Keywords

Exelixis, EXEL, oncology, cancer, pharmaceuticals, biotechnology, CABOMETYX, cabozantinib, zanzalintinib, STELLAR-303, CABINET, renal cell carcinoma, neuroendocrine tumors, colorectal cancer, drug development, clinical trials, FDA, EMA, stock repurchase, financial results, Q3 2025, earnings, R&D, EPS, revenue, corporate reorganization